Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05189808 · ClinicalTrials.gov registry record
Radiofrequency Ablation for BIII Thyroid Nodules
A clinical trial of Indeterminate Bethesda III Thyroid Nodules, sponsored by Columbia University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05189808 is a study of Indeterminate Bethesda III Thyroid Nodules that is actively recruiting participants, run by Columbia University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05189808, a study of Indeterminate Bethesda III Thyroid Nodules, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this observational chart review study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of indeterminate thyroid nodules before and after RFA procedure. This is a data collection study in which the investigators ask patients to give access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target area. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency Ablation
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2027-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05189808
The ClinicalTrials.gov registry entry for NCT05189808 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Indeterminate Bethesda III Thyroid Nodules appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT05189808 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05189808 about?
NCT05189808 is a clinical study titled "Radiofrequency Ablation for BIII Thyroid Nodules". The purpose of this observational chart review study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of indeterminate thyroid nodules before and after RFA procedure. This is a data collection study in which the investigators ask patients to give access to inform...
What is the current status of trial NCT05189808?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-08-01. Estimated completion is 2027-08.
What conditions does trial NCT05189808 study?
This clinical trial studies the following conditions: Indeterminate Bethesda III Thyroid Nodules.
What interventions are being tested in trial NCT05189808?
The interventions under investigation include: Radiofrequency Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05189808?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05189808 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.